To include your compound in the COVID-19 Resource Center, submit it here.

China approves Novo's Tresiba

China FDA approved once-daily Tresiba insulin degludec (NN1250) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to treat Type I and

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE